1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6085820D142918CC485256C7C007B999A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/developing-a-diagnostic-test-the-pharmaceutical-industry-perspective?opendocument
18
19opendocument
203.235.139.152
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Alliances and Partnerships

Developing a Diagnostic Test: The Pharmaceutical Industry Perspective

DB Image

ID: 4357


Features:

Graphics


Words: 1,706


Published: Pre-2016


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
This 6-page document summarizes the key factors that guide pharmaceutical companies' thinking on pairing therapeutics with diagnostic tests. Discussed are the aspects of this pairing, including how pharmaceutical companies typically structure relationships with diagnostic companies or divisions, and what they view as the upside and downside to aligning therapeutics with diagnostics.

Industries Profiled:
Pharmaceutical; Diagnostic; Research; Manufacturing; Biotech; Consumer Products; Medical Device


Companies Profiled:
Eli Lilly; bioMerieux; Visible Genetics; LipoScience; LabCorp; Tibotec-Virco; Cholestech; Diagnology; Bayer; Focus Technologies; Abbott Laboratories; AstraZeneca; GlaxoSmithKline; Becton Dickinson; Roche

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.